MedTrace Logo

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

NCT05717686 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-02-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.

Conditions

Interventions

DRUG

AHB-137 injection

AHB-137 will be administered

DRUG

Placebo

Placebo will be administered

Sponsors & Collaborators

  • AusperBio Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Ed Gane · University of Auckland, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2025-01-07
Completion
2025-01-07
FDA Drug
Yes

Countries

  • United States
  • Hong Kong
  • New Zealand
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05717686 on ClinicalTrials.gov